6.4 Intranasal (LAIV), Oral (Rotavirus), and Alternative Route Administration Techniques

Intranasal (LAIV), Oral (Rotavirus), and Alternative Route Administration Techniques

Core Clinical Principle: Non-injectable and alternative route vaccines stimulate mucosal and specialized localized immunity at the primary portal of pathogen entry. Administering mucosal vaccines (intranasal, oral) requires strict adherence to manufacturer device mechanics, patient behavioral coaching, and clinical redosing protocols that differ fundamentally from injectable vaccines.

While injectable vaccines represent the majority of immunization encounters, pharmacy technicians regularly prepare, dispense, and assist with non-injectable platforms. Mastering the nuances of Live Attenuated Influenza Vaccine (LAIV), Oral Rotavirus Vaccine, and Intradermal (ID) techniques is vital for comprehensive practice and PTCB certification.

1. Intranasal Vaccine Administration: Live Attenuated Influenza Vaccine (LAIV3 / FluMist)

FluMist is the only intranasally administered vaccine routinely used in the United States. It contains cold-adapted, temperature-sensitive, live attenuated influenza virus strains capable of replicating in the cooler nasopharyngeal mucosa (~25°C) to induce local secretory IgA and systemic IgG/T-cell immunity without replicating in the warmer lower respiratory tract (37°C).

+-----------------------------------------------------------------------------+
|                   FLUMIST TRIVALENT SPRAYER ARCHITECTURE                 |
|                                                                             |
|   [ PROTECTIVE RUBBER TIP CAP ]  <-- Remove immediately prior to use        |
|               |                                                             |
|               v                                                             |
|        +-------------+                                                      |
|        | NOZZLE TIP  |  <-- Inserts shallowly into nares (nostril)          |
|        +-------------+                                                      |
|        | GLASS VIAL  |  <-- Contains 0.2 mL total suspension                |
|        +-------------+                                                      |
|               |                                                             |
|               v                                                             |
|     [ DOSE-DIVIDER CLIP ] <-- Plastic clip on plunger rod; BLOCKS at 0.1 mL |
|               |                                                             |
|               v                                                             |
|      +---------------+                                                      |
|      |  PLUNGER ROD  |  <-- Depressed to spray 1st half; remove clip;       |
|      +---------------+      depress remainder for 2nd half.                 |
+-----------------------------------------------------------------------------+

Product Specifications and Cold Chain Storage

• Dose Volume: Exactly 0.2 mL total volume (0.1 mL sprayed into each nostril).
• Storage Temperature: Strict refrigeration at 2°C to 8°C (36°F to 46°F). Must NEVER be frozen.
• Packaging: Single-use, needle-free, pre-filled nasal sprayer device.

2. Step-by-Step LAIV Administration Procedure

Administering FluMist requires a standardized sequence to ensure accurate dose division across both nares:

+-----------------------------------------------------------------------------+
|                   FLUMIST STEP-BY-STEP ADMINISTRATION FLOW                  |
|                                                                             |
|  STEP 1: INSPECTION & WARMING                                               |
|  - Remove sprayer from refrigerator. Check expiration date and lot number.  |
|  - Solution should be clear to pale yellow, free of particulate matter.     |
|                                                                             |
|  STEP 2: PATIENT POSITIONING & COACHING                                     |
|  - Patient must sit in an upright position with head tilted slightly back.  |
|  - Instruct the patient: "Breathe normally through your nose. Do NOT sniff, |
|    snort, or inhale deeply during administration."                          |
|                                                                             |
|  STEP 3: REMOVE PROTECTIVE TIP CAP                                          |
|  - Pull the rubber tip protector cap straight off the nozzle.               |
|  - Verify the plastic dose-divider clip remains seated on the plunger rod.  |
|                                                                             |
|  STEP 4: FIRST NOSTRIL ADMINISTRATION (0.1 mL)                              |
|  - Insert the nozzle tip just inside the opening of the first nostril.      |
|  - Depress the plunger rod rapidly in a SINGLE, FIRM MOTION until the       |
|    dose-divider clip hits the sprayer barrel and stops the plunger.         |
|                                                                             |
|  STEP 5: REMOVE DOSE-DIVIDER CLIP                                           |
|  - Withdraw the sprayer from the first nostril.                             |
|  - Pinch and pull the plastic dose-divider clip off the plunger rod.        |
|                                                                             |
|  STEP 6: SECOND NOSTRIL ADMINISTRATION (0.1 mL)                             |
|  - Insert nozzle tip just inside the opening of the second nostril.         |
|  - Depress the plunger rod firmly all the way until it bottoms out.         |
|                                                                             |
|  STEP 7: DISPOSAL                                                           |
|  - Discard the spent sprayer in standard pharmaceutical waste.              |
+-----------------------------------------------------------------------------+

Critical Clinical Scenario: The Post-Administration Sneeze

A common exam question and clinical scenario occurs when a patient sneezes immediately during or after LAIV administration:

• CDC / ACIP Guideline: DO NOT REPEAT THE DOSE.
• Scientific Rationale: The cold-adapted viral particles adhere almost instantly to the rich mucosal epithelial surface of the nasopharynx. Sneezing, swallowing, or mild rhinorrhea does not diminish the immune response or reduce clinical efficacy.

Antiviral Medication Timing Rules

Because LAIV is a live viral vaccine, circulating anti-influenza antiviral medications will neutralize the attenuated strains:

• Pre-Vaccine Deferral: Patients must not have received oseltamivir or zanamivir within 48 hours, peramivir within 5 days, or baloxavir marboxil within 17 days prior to LAIV administration.
• Post-Vaccine Deferral: Antiviral medications should not be administered for at least 14 days following LAIV receipt, unless medically necessary.

3. Contraindications and Precautions Specific to LAIV

LAIV has significantly more contraindications than inactivated injectable influenza vaccines:

+-----------------------------------------------------------------------------+
|                     LAIV CONTRAINDICATION SCREENING MATRIX                  |
|                                                                             |
|  ABSOLUTE CONTRAINDICATIONS TO LAIV (Must Receive Inactivated IIV3 / RIV3)  |
|  -------------------------------------------------------------------------  |
|  • Age younger than 2 years OR age 50 years and older                       |
|  • Pregnancy (any trimester)                                                |
|  • Severe immunocompromise (HIV with low CD4, chemotherapy, biologics, etc.)|
|  • Concomitant aspirin- or salicylate-containing therapy in children/teens   |
|    (due to the established risk of Reye syndrome)                           |
|  • Children aged 2 through 4 years with active asthma or a documented       |
|    wheezing episode within the preceding 12 months                          |
|  • Anatomic cerebrospinal fluid (CSF) leaks or cochlear implants             |
|  • Severe, life-threatening anaphylactic reaction to any vaccine component  |
|  • Close contacts / caregivers of severely immunocompromised persons who     |
|    require a protected environment (e.g., bone marrow transplant unit)       |
+-----------------------------------------------------------------------------+

4. Oral Vaccine Administration: Rotavirus Vaccines (Rotarix vs. RotaTeq)

Rotavirus is the leading cause of severe dehydrating diarrhea in infants and young children worldwide. In the United States, two live oral rotavirus vaccines are licensed and recommended:

+-----------------------------------------------------------------------------+
|                   STEP-BY-STEP ORAL ROTAVIRUS ADMINISTRATION                |
|                                                                             |
|  STEP 1: PATIENT POSITIONING                                                |
|  - Place infant in a semi-reclined, seated position on caregiver's lap.     |
|                                                                             |
|  STEP 2: PREPARE APPLICATOR / TUBE                                          |
|  - Twist off cap from squeezable tube (RotaTeq) or oral syringe (Rotarix).  |
|                                                                             |
|  STEP 3: BUCCAL MUCOSA INSTILLATION                                         |
|  - Gently squeeze the infant's cheeks or stimulate the sucking reflex.      |
|  - Place the applicator tip INSIDE THE CHEEK (buccal mucosa) toward the     |
|    back of the mouth.                                                       |
|  - Administer the liquid SLOWLY in small increments along the inner cheek.  |
|  - Allow the infant time to swallow naturally.                              |
|                                                                             |
|  SAFETY WARNING: NEVER SQUIRT DIRECTLY INTO THE PHARYNX (CHOKING RISK).     |
+-----------------------------------------------------------------------------+

The Regurgitation / Spitting-Up ACIP Standard

• ACIP Clinical Guideline: If an infant spits up, vomits, or regurgitates any portion of an oral rotavirus vaccine dose, DO NOT REPEAT OR READMINISTER THE DOSE.
• Clinical Action: Document the dose as administered and continue the remaining doses in the routine series according to the ACIP age schedule.

5. Specialized and Historical Routes: Intradermal (ID) Injection

Intradermal (ID) administration deposits microscopic volumes of antigen directly into the dermis (the vascular collagen layer between epidermis and subcutaneous adipose), which contains an extraordinarily high concentration of antigen-presenting Langerhans dendritic cells.

+-----------------------------------------------------------------------------+
|                       INTRADERMAL (ID) INJECTION DYNAMICS                   |
|                                                                             |
|         Syringe at 10°–15° Angle                                            |
|         \                                                                   |
|          \  [ Bevel Facing UP ]                                             |
|           \====>  [ EPIDERMIS ]                                             |
|            \---  (========== WHEAL / BLEB (6-10 mm) ==========)             |
|             \    [ DERMIS ]                                                 |
|              ---------------------------------------------------            |
|                  [ SUBCUTANEOUS FAT ]                                       |
+-----------------------------------------------------------------------------+

Intradermal Specifications and Applications

• Equipment: 26 to 28 gauge needle, 3/8 to 1/2 inch in length, 1 mL syringe.
• Insertion Angle: 10 to 15 degrees almost parallel to the skin surface, with the needle bevel facing UP.
• Endpoint: Injection of 0.1 mL produces a discrete, pale, elevated cutaneous wheal (bleb) resembling a mosquito bite (6 to 10 mm in diameter).
• Primary Applications:
  1. Tuberculin Skin Testing (Mantoux PPD): 0.1 mL 5 TU PPD on volar forearm.
  2. JYNNEOS Mpox Alternative Regimen: For eligible adults, 0.1 mL ID may be used under the current EUA; CDC notes that adequate supply permits preference for the standard 0.5 mL SC regimen.
  3. U.S. Rabies Vaccination: Current U.S. rabies vaccines use the intramuscular route; do not substitute international WHO intradermal regimens in a U.S. protocol.